Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
Researchers sought to determine whether adding bortezomib to bendamustine-rituximab induction therapy would improve survival in patients with mantle cell lymphoma.
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
Researchers sought to determine whether a combination therapy of romidepsin and lenalidomide would be effective as initial therapy for patients with PTCL.
Researchers sought to determine whether idecabtagene vicleucel would have durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma.
Researchers sought to determine whether penpulimab would have efficacy and a low rate of serious AEs in patients with relapsed/refractory classic Hodgkin lymphoma.
Researchers sought to determine whether selinexor could be safely combined with pomalidomide and dexamethasone in heavily pretreated patients with multiple myeloma.
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
A 45-mg starting dose, reduced to 15 mg, produced the best outcome.
The combination produced 2 complete responses.
